An integrated pharmacogenomic analysis of doxorubicin response using genotype information on DMET genes

Genetic variations like single nucleotide polymorphism (SNPs) in drug metabolizing and transporter (DMET) genes can impact their downstream function and behavior, and play a crucial role in the pharmacokinetics of substrate drugs. These polymorphisms can alter drug response in some patients leading to adverse drug response like toxicity, resistance or lack of sensitivity. We have identified variants in a number of genes that are significantly associated with doxorubicin response in an effort to enhance personalized medicine in the clinic.